We are delighted to announce a three-year strategic partnership with upsource by solutions to enhance Business Process Outsourcing (BPO) in Saudi Arabia. This collaboration will leverage Upsource by Solutions' profound local expertise and Cognizant's advanced AI and automation technologies to: • Improve operational efficiency • Elevate customer experience • Foster scalable growth in the region For more information, please visit: http://cgnz.at/6044UYlHp
About us
Cognizant (Nasdaq-100: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant.
- Website
-
https://www.cognizant.com
External link for Cognizant
- Industry
- IT Services and IT Consulting
- Company size
- 10,001+ employees
- Headquarters
- Teaneck, New Jersey
- Type
- Public Company
- Specialties
- Interactive, Intelligent Process Automation, Digital Engineering, Industry & Platform Solutions, Internet of Things, Artificial Intelligence, Cloud, Data , Healthcare, Banking, Finance , Fintech, Manufacturing, Retail, Technology , and Salesforce
Locations
Employees at Cognizant
Updates
-
We are pleased to announce the renewal of our partnership with KBC Group until 2027. This extension reaffirms our commitment to supporting KBC Group's IT and business transformation across a comprehensive range of services, including application development, data services, infrastructure, and quality engineering. Isabel Van Mele, Chief Information Officer of KBC Bank & Verzekering, stated, "Cognizant's ability to provide various IT services, focusing on quality, stability, and cost-effectiveness, makes it an important partner for KBC. We look forward to continuing our collaboration to achieve our organizational objectives." Together, we aim to create superior customer experiences, support innovation, and maintain operational excellence. http://cgnz.at/6044UY5fi
-
-
Generative AI is transforming the way businesses unlock new sources of revenue. From automating content creation to enhancing personalization, it offers organizations the opportunity to drive innovation and efficiency. By leveraging AI to unlock trapped value, companies can stay ahead of the curve and create new, profitable avenues. In a new blog post, Surya Gummadi, Executive VP and President, Cognizant Americas, explores how businesses can leverage generative AI to discover untapped potential. Read more: http://cgnz.at/6045U59yN
-
-
With a combination of homegrown capabilities and strategic acquisitions, Cognizant continues to integrate AI throughout the company to boost operational efficiency while sharing findings with clients. Our CEO Ravi Kumar S sat down with CRN to discuss Cognizant's role in leading the charge in AI innovation, positioning the company as a key player in the AI-led services landscape. Read the full article: http://cgnz.at/6045U5glU
-
-
Cognizant is delivering digital transformation for the world’s leading brands – helping businesses scale AI, cloud, and cybersecurity innovation. See how we’re driving impact across industries in our latest earnings report. Read the full press release here: http://cgnz.at/6040Uel7p #Innovation #ClientSuccess #DigitalTransformation
-
Cognizant Q4 & FY'24 earnings are in, swipe through to explore: ➡️ Fourth quarter revenue of $5.1 billion increased 6.8% YOY, at the high end of our guidance range ➡️ Full-year revenue of $19.7 billion increased 2.0% YOY ➡️ Full-year operating margin of 14.7%, increased 80 basis points YOY ➡️ Trailing 12-month bookings of $27.1 billion, up 3% YOY ➡️ Cash dividend increased 3% to $0.31 per share for Q1 2025 Read more: http://cgnz.at/6047UeYcd
-
Some careers come full circle. 🔄 We’re a foundation for growth, a hub for innovation, and a community that welcomes people back. Many of our associates leave to explore new paths, only to return because of the culture, the people, and the opportunities to make an impact. Hear from our returning associates about why they made the move (again).
-
In a new milestone for our strategic partnership with ServiceNow, we’ve been elevated to Global Elite status, the highest level of partnership recognition within the ServiceNow Partner Program. This achievement reflects our commitment to delivering innovative AI solutions and exceptional customer value to global clients through the ServiceNow platform.
-
-
The life sciences industry is experiencing unprecedented innovation, with companies increasingly focused on accelerating clinical development processes to enhance client outcomes. Today, Cognizant announced it has expanded its agreement with Medidata Solutions, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for Medidata’s life sciences clients and expand the strategic alliance partnership. “We are thrilled to accelerate our work with Medidata to help mutual clients leverage next-generation AI-enabled clinical capabilities on the unified Medidata Platform,” said Mohammad Haque, SVP, Global Large Deals Lead and Business Unit Head, Life Sciences, of Cognizant. “Our collaboration aims to unlock the full potential of clients’ clinical data and processes, improving user satisfaction and empowering them to make better-informed decisions faster for improved patient outcomes.” Read more: http://cgnz.at/6046UVNQn
-
-
We are thrilled to announce the expansion of our partnership with Gilead Sciences. Leveraging machine learning and generative AI, this collaboration aims to unlock even greater value for Gilead, addressing multiple use cases across customer service, employee interactions, and business value management. Over the last decade, we’ve helped support Gilead's global IT infrastructure, platforms, applications, and advanced analytics, and led initiatives designed to accelerate its digital transformation. This expanded collaboration is intended to create capacity to allow Gilead to continue its focus and mission, aimed at discovering and delivering critical medicines for cancer, HIV, and other diseases.
-